Literature DB >> 19269164

MC1R variant alleles and malignant melanoma risk in Israel.

Gilli Galore-Haskel1, Esther Azizi, Hamida Mohamdi, Alon Scope, Valérie Chaudru, Yael Laitman, Frida Barak, Felix Pavlotsky, Florence Demenais, Eitan Friedman.   

Abstract

To evaluate the contribution of MC1R variants to malignant melanoma risk in Israeli Jews, sequencing of the MC1R gene was performed in 132 melanoma patients and 184 ethnically matched controls. Overall, 22 MC1R variants were detected, two were novel (M73I and 496_497insG). Using age and sex-adjusted logistic regression, one specific variant, R151C, conferred significantly increased melanoma risk among Ashkenazim (OR=2.6, 95% CI: 1.3-5.3; p=0.05 after Bonferroni correction). A gene dosage effect was noted, with significantly increased melanoma risk being observed in subjects with at least two variants whether when all variants are pooled (OR=4.8, 95% CI: 2.0-11.2; p=0.002 after Bonferroni correction) or when red hair colour (RHC) variants and non-RHC variants are distinguished (OR=7.6, 95% CI: 2.8-20.3; p=0.0004 after Bonferroni correction). If further studies support these findings, the assessment of MC1R status may be useful in identifying Jewish Israeli individuals at high risk for melanoma.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19269164     DOI: 10.1016/j.ejca.2009.02.001

Source DB:  PubMed          Journal:  Eur J Cancer        ISSN: 0959-8049            Impact factor:   9.162


  4 in total

1.  Pharmacologic induction of epidermal melanin and protection against sunburn in a humanized mouse model.

Authors:  Alexandra Amaro-Ortiz; Jillian C Vanover; Timothy L Scott; John A D'Orazio
Journal:  J Vis Exp       Date:  2013-09-07       Impact factor: 1.355

2.  Association of MC1R variants and host phenotypes with melanoma risk in CDKN2A mutation carriers: a GenoMEL study.

Authors:  F Demenais; H Mohamdi; V Chaudru; A M Goldstein; J A Newton Bishop; D T Bishop; P A Kanetsky; N K Hayward; E Gillanders; D E Elder; M F Avril; E Azizi; P van Belle; W Bergman; G Bianchi-Scarrà; B Bressac-de Paillerets; D Calista; C Carrera; J Hansson; M Harland; D Hogg; V Höiom; E A Holland; C Ingvar; M T Landi; J M Lang; R M Mackie; G J Mann; M E Ming; C J Njauw; H Olsson; J Palmer; L Pastorino; S Puig; J Randerson-Moor; M Stark; H Tsao; M A Tucker; P van der Velden; X R Yang; N Gruis
Journal:  J Natl Cancer Inst       Date:  2010-09-28       Impact factor: 13.506

3.  The melanocortin 1 receptor (Mc1r) variants do not account for the co-occurrence of Parkinson's disease and malignant melanoma.

Authors:  Sandra Elincx-Benizri; Rivka Inzelberg; Lior Greenbaum; Oren S Cohen; Gilad Yahalom; Yael Laitman; Ruth Djaldetti; Yael Orlev; Alon Scope; Esther Azizi; Eitan Friedman; Sharon Hassin-Baer
Journal:  J Mol Neurosci       Date:  2014-10-05       Impact factor: 3.444

4.  Melanocortin-1 receptor, skin cancer and phenotypic characteristics (M-SKIP) project: study design and methods for pooling results of genetic epidemiological studies.

Authors:  Sara Raimondi; Sara Gandini; Maria Concetta Fargnoli; Vincenzo Bagnardi; Patrick Maisonneuve; Claudia Specchia; Rajiv Kumar; Eduardo Nagore; Jiali Han; Johan Hansson; Peter A Kanetsky; Paola Ghiorzo; Nelleke A Gruis; Terry Dwyer; Leigh Blizzard; Ricardo Fernandez-de-Misa; Wojciech Branicki; Tadeusz Debniak; Niels Morling; Maria Teresa Landi; Giuseppe Palmieri; Gloria Ribas; Alexander Stratigos; Lynn Cornelius; Tomonori Motokawa; Sumiko Anno; Per Helsing; Terence H Wong; Philippe Autier; José C García-Borrón; Julian Little; Julia Newton-Bishop; Francesco Sera; Fan Liu; Manfred Kayser; Tamar Nijsten
Journal:  BMC Med Res Methodol       Date:  2012-08-03       Impact factor: 4.615

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.